Sequential chemoimmunotherapy of experimental visceral leishmaniasis using a single low dose of liposomal amphotericin B and a novel DNA vaccine candidate

  • Seifert K
  • Juhls C
  • Salguero F
 et al. 
  • 2


    Mendeley users who have this article in their library.
  • N/A


    Citations of this article.


Combination therapies for leishmaniasis, including drugs and immunomodulators, are one approach to shorten treatment courses and to improve the treatment of complex manifestations of the disease. We evaluated a novel T-cell-epitope-enriched DNA vaccine candidate (LEISHDNAVAX) as host-directed immunotherapy in combination with a standard antileishmanial drug in experimental visceral leishmaniasis. Here we show that the DNA vaccine candidate can boost the efficacy of a single suboptimal dose of liposomal amphotericin B in C57BL/6 mice.

Author-supplied keywords

  • Amphotericin B/*therapeutic use
  • Animals
  • Antiprotozoal Agents/*therapeutic use
  • Female
  • Immunotherapy/methods
  • Leishmaniasis, Visceral/*drug therapy
  • Mice
  • Mice, Inbred C57BL
  • Vaccines, DNA/*therapeutic use

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document


  • K Seifert

  • C Juhls

  • F J Salguero

  • S L Croft

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free